One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients
Open accessAbstract
OBJECTIVE: Treatment with most antipsychotics is associated with an increased risk of weight gain and metabolic disturbances. In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. The aim of this study was to investigate whether the beneficial effects of the 16-week intervention were sustained beyond the intervention period. METHOD: One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide, and lipids comparing 1-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels. RESULTS: From end of treatment to the 1-year follow-up, body weight had increased in the liraglutide-treated group. However, compared to baseline levels, the placebo-subtracted body weight loss remained significantly reduced (-3.8 kg, 95% CI: -7.3 to -0.2, P = 0.04). Fasting glucose, glycated hemoglobin, C-peptide, and lipids had each returned to baseline levels 1 year after stopping liraglutide. CONCLUSION: The body weight reduction during 16 weeks of liraglutide treatment was partially sustained 1 year after the intervention was completed. However, the improvements in other metabolic parameters returned to baseline levels.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other observational studies all found liraglutide beneficial.
“These findings are supported by other observational studies [51,52,58,59]; all of which found liraglutide beneficial as previously summarised in Table 2.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [59]
Where commented on, no significant deterioration in mental illness was reported with liraglutide.
“However, where commented on, no significant deterioration in mental illness was reported [55,57,59].”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [59]
Maccora et al. found no statistical difference in response to liraglutide between its mental illness, eating disorder, and non-mental-illness groups.
“Also notable was an observational study by Maccora et al. of between 94 [51] and 100 [59] subjects also found no statistical difference in response to liraglutide between its mental illness, eating disorder, and non-mental-illness groups.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [59]
The Accepted Article flow diagram describes a randomized comparison of liraglutide and placebo, and the Baseline-to-One-year Follow-up section reports outcomes for those two groups. Our copy does not report a Maccora observational study or compare liraglutide responses among mental-illness, eating-disorder, and non-mental-illness groups (searched for Maccora and those groups). (LLM, conf=0.78)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,482 · see citing works
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069 · see citing works
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works
2. Classification and Diagnosis of Diabetes: <i>Standards of Medical Care in Diabetes—2018</i>
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159 · see citing works
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · see citing works
The clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed Central · Cited by 1,952 · see citing works
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729 · see citing works
Self-citationSecond-Generation (Atypical) Antipsychotics and Metabolic Effects
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,334 · see citing works
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271 · see citing works
Self-citationDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · see citing works
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · see citing works
Howes, O. D., McCutcheon, R. A., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,145 · see citing works
Self-citationSchizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070 · see citing works
Excess early mortality in schizophrenia.
Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153657 · Cited by 913 · cited 1× · see citing works
“Patients with schizophrenia have a reduced life expectancy of 20 years compared to the background population (1).”
Backgroundon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842 · see citing works
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820 · see citing works
Self-citationO'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · see citing works
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · see citing works
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659 · see citing works
Self-citationSiskind, D. J., McCartney, L., Goldschlager, R., & Kisely, S. R. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 605 · see citing works
A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness
Daumit, G. L., Dickerson, F. B., Wang, N.-Y., Dalcin, A., Jerome, G. J., Anderson, C. A. M., Young, D. R., Frick, K. D., Yu, A., Gennusa, J. V., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214530 · Cited by 523 · cited 1× · see citing works
“…type 2 diabetes (T2D) and consequently cardiovascular disease (2– 7 In antipsychotic-treated patients, only modest or no reductions in cardiovascular risk factors have been reported with lifestyle interventions, e.g. diet, exercise and reduction of alcohol and tobacco consumption (18–20).”
BackgroundVilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430 · see citing works
Self-citationSiskind, D. J., Siskind, V., & Kisely, S. R. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717718167 · Cited by 394 · see citing works
Balk, E. M., Earley, A., Raman, G., Avendano, E. A., Pittas, A. G., & Remington, P. L. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0452 · Cited by 371 · see citing works
Global Assessment of Functioning (GAF): properties and frontier of current knowledge
Aas, I. M. (2010) · Annals of General Psychiatry · doi:10.1186/1744-859x-9-20 · Cited by 341 · see citing works
Self-report quality of life measure for people with schizophrenia: The SQLS
Wilkinson, G., Hesdon, B., Wild, D. J., Cookson, R., Farina, C., Sharma, V. K., Fitzpatrick, R. M., & Jenkinson, C. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.1.42 · Cited by 315 · see citing works
Antipsychotic drugs and obesity
Correll, C. U., Lencz, T., & Malhotra, A. K. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.010 · Cited by 307 · see citing works
Self-citationCooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292 · see citing works
Henderson, D. C., Vincenzi, B., Andrea, N. V., Ulloa, M., & Copeland, P. M. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00115-7 · Cited by 288 · see citing works
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Gottwald‐Hostalek, U., Gwilt, M., & Hildemann, S. K. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278 · see citing works
Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250 · see citing works
Self-citationVermeulen, J. M., van Rooijen, G., van de Kerkhof, M. P. J., Sutterland, A. L., Correll, C. U., & de Haan, L. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby052 · Cited by 246 · see citing works
Self-citationMaayan, L. A., Vakhrusheva, J., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.21 · Cited by 230 · see citing works
Self-citation7. Approaches to Glycemic Treatment
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s010 · Cited by 225 · see citing works
Incretin hormones and the satiation signal
Holst, J. J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.208 · Cited by 189 · see citing works
Caemmerer, J., Correll, C. U., & Maayan, L. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.017 · Cited by 182 · see citing works
Speyer, H., Christian Brix Nørgaard, H., Birk, M., Karlsen, M., Storch Jakobsen, A., Pedersen, K., Hjorthøj, C., Pisinger, C., Gluud, C., Mors, O., et al. (2016) · World Psychiatry · doi:10.1002/wps.20318 · Cited by 153 · see citing works
Stubbs, B., Koyanagi, A., Veronese, N., Vancampfort, D., Solmi, M., Gaughran, F., Carvalho, A. F., Lally, J., Mitchell, A. J., Mugisha, J., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0734-z · Cited by 151 · see citing works
Self-citationMudaliar, U., Zabetian, A., Goodman, M., Echouffo-Tcheugui, J. B., Albright, A. L., Gregg, E. W., & Ali, M. K. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002095 · Cited by 146 · see citing works
Jarskog, L. F., Hamer, R. M., Catellier, D. J., Stewart, D. D., LaVange, L., Ray, N., Golden, L. H., Lieberman, J. A., Stroup, T. S., & for the METS Investigators (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12010127 · Cited by 145 · see citing works
Siskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13522 · Cited by 144 · see citing works
Self-citationThe impact of clozapine on hospital use: a systematic review and meta-analysis
Land, R., Siskind, D., McArdle, P., Kisely, S., Winckel, K., & Hollingworth, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12700 · Cited by 141 · see citing works
Metformin for clozapine associated obesity: a systematic review and meta-analysis
Siskind, D. J., Leung, J., Russell, A. W., Wysoczanski, D., & Kisely, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156208 · Cited by 122 · see citing works
Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
Kim, S. H., Abbasi, F., Lamendola, C. A., Liu, A., Ariel, D., Schaaf, P., Grove, K., Tomasso, V., Ochoa, H., Liu, Y. V., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0354 · Cited by 118 · see citing works
Ishøy, P. L., Knop, F. K., Broberg, B. V., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Glenthøj, B. Y., & Ebdrup, B. H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12795 · Cited by 102 · see citing works
Liraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101 · see citing works
Siskind, D. J., Russell, A. W., Gamble, C., Winckel, K., Mayfield, K., Hollingworth, S., Hickman, I., Siskind, V., & Kisely, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13167 · Cited by 98 · see citing works
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49 · see citing works
Ariel, D., Kim, S. H., Abbasi, F., Lamendola, C. A., Liu, A., & Reaven, G. M. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.06.010 · Cited by 37 · see citing works
Ebdrup, B. H., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Knop, F. K., & Glenthøj, B. Y. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13204 · Cited by 35 · see citing works
Ebdrup, B. H., Knop, F. K., Ishøy, P. L., Rostrup, E., Fagerlund, B., Lublin, H., & Glenthøj, B. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-92 · Cited by 34 · see citing works
Larsen, J., Vedtofte, L., Holst, J., Oturai, P., Kjær, A., Corell, C. U., Vilsbøll, T., & Fink-Jensen, A. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004227 · Cited by 20 · see citing works
Self-citationEricsson, Å., Glah, D. R., Lorenzi, M. F., Jansen, J. P., & Fridhammar, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191953 · Cited by 17 · see citing works
Hunt, B., McConnachie, C. C., Gamble, C. L., & Dang‐Tan, T. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1347793 · Cited by 14 · see citing works
Barnett, A. H., Arnoldini, S., Hunt, B., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13318 · Cited by 11 · see citing works
Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain—Reply
Fink‐Jensen, A., Correll, C. U., & Vilsbøll, T. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2702 · Cited by 4 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes. JAMA [Internet]. 2015 Aug 18 [cited 2015 Aug 18];314(7):687. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26284720
Cited by
Sorted by citations
West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., et al. (2026) · BMJ · doi:10.1136/bmj-2025-085304 · Cited by 174 · see citing works
Tzang, C.-C., Wu, P.-H., Luo, C.-A., Chen, Z.-T., Lee, Y.-T., Huang, E. S., Kang, Y.-F., Lin, W.-C., Tzang, B.-S., & Hsu, T.-C. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103680 · Cited by 73 · see citing works
The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
Zhang, L., Zhang, W., & Tian, X. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2021.1924707 · Cited by 54 · see citing works
Zhang, F., Chen, Z., Wu, D., Tian, L., Chen, Q., Ye, Y., Chen, W., Wu, X., Wu, P., Yuan, W., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103382 · Cited by 54 · see citing works
Lee, K., Abraham, S., & Cleaver, R. (2022) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2022.07.006 · Cited by 53 · see citing works
Wu, H., Yang, W., Guo, T., Cai, X., & Ji, L. (2025) · BMC Medicine · doi:10.1186/s12916-025-04200-0 · Cited by 36 · see citing works
Maccora, C., Ciuoli, C., Goracci, A., Benenati, N., Formichi, C., Pilli, T., Verdino, V., Mnutr, O. N., Bufano, A., Tirone, A., et al. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0169 · Cited by 19 · see citing works
- Authors
- Svensson, C. K., Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, C. T., Correll, C. U., Vilsbøll, T., & Fink‐Jensen, A.
- Affiliations
- Mental Health Services (DK)
- Novo Nordisk (Denmark) (DK)
- University of Copenhagen (DK)
- Psychiatric Centre Copenhagen Rigshospitalet Mental Health Services Capital Region of Denmark, Copenhagen Denmark
- Aalborg University (DK)
- Northwell Health (US)
- Corresponding author
- Fink‐Jensen, A.
- ORCID
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2018-11-28
- Volume
- 139
- Issue
- 1
- Pages
- 26-36
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2899417834
- Cited by
- 66
- References
- 58
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 8 · 2023: 7 · 2022: 8 · 2021: 9 · 2020: 4 · 2019: 4
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Acta Psychiatrica Scandinavica (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (acceptedVersion, other-oa)
- Funders
- Novo Nordisk
- Lundbeckfonden
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, GLP-1 receptor agonists, prediabetes, overweight, obesity, clozapine, olanzapine, schizophrenia spectrum disorders, antipsychotic-induced weight gain, sustained weight loss, glycemic control, HbA1c, C-peptide, fasting blood glucose, serum lipids, one-year follow-up
- MeSH terms
- Liraglutide, Olanzapine, Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Aged, Blood Glucose, Body Weight, C-Peptide, Clozapine, Denmark, Fasting, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Placebos, Prediabetic State, Schizophrenia, Antipsychotic Agents, Overweight, Lipid Metabolism, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
